Patents by Inventor Anna-Karin Tidén
Anna-Karin Tidén has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9580429Abstract: There are disclosed novel compounds of formula (I) wherein R1, R12, L, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardiovascular disorders and respiratory disorders.Type: GrantFiled: September 15, 2014Date of Patent: February 28, 2017Assignee: AstraZeneca ABInventors: Anders Bogevig, Yvonne Lo-Alfredsson, Donald Pivonka, Anna-Karin Tiden
-
Publication number: 20150099769Abstract: There are disclosed novel compounds of formula (I) wherein R1, R12, L, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardiovascular disorders and respiratory disorders.Type: ApplicationFiled: September 15, 2014Publication date: April 9, 2015Inventors: Anders BOGEVIG, Yvonne LO-ALFREDSSON, Donald PIVONKA, Anna-Karin TIDEN
-
Patent number: 8859568Abstract: There are disclosed novel compounds of formula (I) wherein R1, R12, L, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardiovascular disorders and respiratory disorders.Type: GrantFiled: November 3, 2010Date of Patent: October 14, 2014Assignee: Astrazeneca ABInventors: Anders Bögevig, Yvonne Lo-Alfredsson, Donald Pivonka, Anna-Karin Tidén
-
Patent number: 8765939Abstract: The present invention provides compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof, as well as processes for their preparation, pharmaceutical compositions containing them and their use in therapy.Type: GrantFiled: August 16, 2012Date of Patent: July 1, 2014Assignees: AstraZeneca AB, Dainippon Sumitomo Pharma Co., Ltd.Inventors: Nicholas J. Bennett, Thomas McInally, Tobias Mochel, Stephen Thom, Anna-Karin Tidén
-
Publication number: 20130045955Abstract: The present invention provides compounds of formula (I) herein R1, R2, R3 and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof, as well as processes for their preparation, pharmaceutical compositions containing them and their use in therapy.Type: ApplicationFiled: August 16, 2012Publication date: February 21, 2013Inventors: Nicholas J. Bennett, Thomas MCINALLY, Tobias MOCHEL, Stephen Thom, Anna-Karin Tidén
-
Patent number: 8236951Abstract: There is disclosed the use of a compound of formula (Ia) or (Ib) wherein R1, R2, R3, R4, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of the enzyme myeloperoxidase (MPO) is beneficial. Certain novel compounds of formula (Ia) or (Ib) and pharmaceutically acceptable salts thereof are disclosed, together with processes for their preparation. The compounds of formulae (Ia) and (Ib) are MPO inhibitors and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders.Type: GrantFiled: August 4, 2008Date of Patent: August 7, 2012Assignee: AstraZeneca ABInventors: Sverker Hanson, Gunnar Nordvall, Anna-Karin Tiden
-
Patent number: 8026244Abstract: There are disclosed novel compounds of Formula (I) wherein L, R1, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardio- and cerebrovascular atherosclerotic disorders and peripheral artery disease and respiratory disorders.Type: GrantFiled: April 12, 2007Date of Patent: September 27, 2011Assignee: AstraZeneca ABInventors: Anna-Karin Tiden, Jenny Viklund
-
Patent number: 7943625Abstract: The present invention relates to a compound according to Formula (I) wherein R1 is selected from C1-C6 alkyl, and said C1-C6 alkyl is substituted with C1-C6 alkoxy; and at least one of said C1-C6 alkyl or said C1-C6 alkoxy is branched; or a pharmaceutically acceptable salt thereof, solvate or solvate of a salt thereof, as well as, to compositions containing at least one compound according to Formula (I) and methods of treating at least one disease or condition therewith.Type: GrantFiled: June 1, 2007Date of Patent: May 17, 2011Assignee: AstraZeneca ABInventor: Anna-Karin Tidén
-
Publication number: 20110059996Abstract: There are disclosed novel compounds of formula (I) wherein R1, R12, L, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardiovascular disorders and respiratory disorders.Type: ApplicationFiled: November 3, 2010Publication date: March 10, 2011Inventors: Anders BÖGEVIG, Yvonne LO-ALFREDSSON, Donald PIVONKA, Anna-Karin TIDÉN
-
Patent number: 7829707Abstract: There are disclosed novel compounds of formula (I) wherein R1, R12, L, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardiovascular disorders and respiratory disorders.Type: GrantFiled: December 5, 2005Date of Patent: November 9, 2010Assignee: AstraZeneca ABInventors: Anders Bogevig, Yvonne Lo-Alfredsson, Donald Pivonka, Anna-Karin Tiden
-
Publication number: 20090286813Abstract: There are disclosed novel compounds of Formula (I) wherein R1, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardio- and cerebrovascular atherosclerotic disorders and peripheral artery disease and respiratory disorders.Type: ApplicationFiled: April 12, 2007Publication date: November 19, 2009Applicant: ASTRAZENECA ABInventors: Donald Pivonka, Anna-Karin Tiden, Jenny Viklund
-
Publication number: 20090209524Abstract: The present invention provides compounds of formula (1) wherein R1, R2, R3 and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof, as well as processes for their preparation, pharmaceutical compositions containing them and their use in therapy.Type: ApplicationFiled: November 20, 2008Publication date: August 20, 2009Applicant: AstraZeneca ABInventors: Nicholas J. BENNETT, Thomas MCINALLY, Tobias MOCHEL, Stephen THOM, Anna-Karin TIDEN
-
Publication number: 20090149475Abstract: There are disclosed novel compounds of Formula (I) wherein L, R1, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardio- and cerebrovascular atherosclerotic disorders and peripheral artery disease and respiratory disorders.Type: ApplicationFiled: April 12, 2007Publication date: June 11, 2009Applicant: ASTRAZENECA ABInventors: Anna-Karin Tiden, Jenny Viklund
-
Publication number: 20090131459Abstract: The present invention relates to a compound according to Formula (I) wherein R1 is selected from C1-C6 alkyl, and said C1-C6 alkyl is substituted with C1-C6 alkoxy; and at least one of said C1-C6 alkyl or said C1-C6 alkoxy is branched; or a pharmaceutically acceptable salt thereof, solvate or solvate of a salt thereof, to compositions containing the compound and the use thereof in therapy.Type: ApplicationFiled: June 4, 2007Publication date: May 21, 2009Applicant: ASTRAZENECA ABInventor: Anna-Karin Tiden
-
Publication number: 20090124640Abstract: The present invention relates to a new compound A: [Chemical formula should be inserted here. Please see paper copy] a process for its preparation, pharmaceutical formulations containing said therapeutically active compound and to the use of said active compound in therapy. The compound is an inhibitor of the enzyme MPO and is thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardiovascular disorders and respiratory disorders.Type: ApplicationFiled: June 4, 2007Publication date: May 14, 2009Applicant: ASTRAZENECA ABInventors: Anna-Karin Tiden, Cecilia Weistrand
-
Publication number: 20080293748Abstract: There is disclosed the use of a compound of formula (Ia) or (Ib) wherein R1, R2, R3, R4, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of the enzyme myeloperoxidase (MPO) is beneficial. Certain novel compounds of formula (Ia) or (Ib) and pharmaceutically acceptable salts thereof are disclosed, together with processes for their preparation. The compounds of formulae (Ia) and (Ib) are MPO inhibitors and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders.Type: ApplicationFiled: August 4, 2008Publication date: November 27, 2008Applicant: ASTRAZENECA ABInventors: Sverker Hanson, Gunnar Nordvall, Anna-Karin Tiden
-
Patent number: 7425560Abstract: There is disclosed the use of a compound of formula (Ia) or (Ib) wherein R1, R2, R3, R4, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of the enzyme myeloperoxidase (MPO) is beneficial. Certain novel compounds of formula (Ia) or (Ib) and pharmaceutically acceptable salts thereof are disclosed, together with processes for their preparation. The compounds of formulae (Ia) and (Ib) are MPO inhibitors and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders.Type: GrantFiled: April 15, 2003Date of Patent: September 16, 2008Assignee: AstraZeneca ABInventor: Anna-Karin Tidén
-
Publication number: 20080221136Abstract: There are disclosed novel compounds of formula (I) wherein R1, R12, L, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardiovascular disorders and respiratory disorders.Type: ApplicationFiled: December 5, 2005Publication date: September 11, 2008Applicant: AstraZeneca ABInventors: Anders Bogevig, Yvonne Lo-Alfredsson, Donald Pivonka, Anna-Karin Tiden
-
Publication number: 20080221133Abstract: The present invention relates to a compound according to Formula (I) wherein R1 is selected from C1-C6 alkyl, and said C1-C6 alkyl is substituted with C1-C6 alkoxy; and at least one of said C1-C6 alkyl or said C1-C6 alkoxy is branched; or a pharmaceutically acceptable salt thereof, solvate or solvate of a salt thereof, as well as, to compositions containing at least one compound according to Formula (I) and methods of treating at least one disease or condition therewith.Type: ApplicationFiled: June 1, 2007Publication date: September 11, 2008Applicant: ASTRAZENECA ABInventor: Anna-Karin Tiden
-
Publication number: 20080096929Abstract: There is disclosed the use of a compound of formula (I), (I) wherein X, Y, W and Q are as defined in the specification, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of the enzyme myeloperoxidase (MPO) is beneficial. Certain novel compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed, together with processes for their preparation. The compounds of formulae (I) are MPO inhibitors and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders.Type: ApplicationFiled: October 24, 2005Publication date: April 24, 2008Applicant: ASTRAZENECA ABInventors: Anna-Karin Tiden, Dominika Turek, Jenny Viklund